FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034118963> ?p ?o ?g. }

• W2034118963 endingPage "641" @default.
• W2034118963 startingPage "633" @default.
• W2034118963 abstract "ObjectiveIntimal hyperplasia is a major obstacle to patency after vein grafting. Despite of a diverse array of trials to prevent it, a satisfactory therapeutic strategy for clinical use has not been established. However, sufficient inhibition of early stages of intimal hyperplasia may prevent this long-term progressive disease. Midkine (MK) is a heparin-binding growth factor that was originally discovered as the product of a retinoic acid-responsive gene. We previously demonstrated that MK-deficient mice exhibit a striking reduction of neointima formation in a restenosis model, which is reversed on systemic MK administration. In this study, we evaluated a strategy of using small interfering RNA (siRNA) targeting MK as a therapy for vein graft failure.MethodsWe first made a highly effective siRNA to rabbit MK. Jugular vein-to-carotid artery interposition vein grafts, which are applied to a low flow condition, were made in Japanese white rabbits. Small interfering RNA mixed with atelocollagen was administrated to the external wall of grafted veins. Cy3-conjugated stabilized siRNA was used to confirm its stability and successful transfer into the vein graft wall. Neointimal hyperplasia was evaluated 4 weeks after the operation. The proliferation index and leukocyte infiltration were determined.ResultsMK expression was induced and reached the maximum level 7 days after operation. Fluorescence of Cy3-labeled siRNA could be detected in the graft wall even 7 days after operation. Knockdown of the gradually increasing expression was achieved by perivascular application of siRNA using atelocollagen. The intima-media ratio and the intima thickness at 28 days after grafting were both reduced >90% by this treatment compared with controls. This phenomenon was preceded by significant reductions of inflammatory cell recruitment to the vessel walls and subsequent cell proliferation in MK siRNA-treated grafts.ConclusionsThese results suggest that midkine is a candidate molecular target for preventing vein graft failure. Furthermore, for clinical applications of siRNA, a single intraoperative atelocollagen-based nonviral delivery method could be a reliable approach to achieve maximal function of siRNA in vivo. This strategy may be a useful and practical form of gene therapy against human vein graft failure. Intimal hyperplasia is a major obstacle to patency after vein grafting. Despite of a diverse array of trials to prevent it, a satisfactory therapeutic strategy for clinical use has not been established. However, sufficient inhibition of early stages of intimal hyperplasia may prevent this long-term progressive disease. Midkine (MK) is a heparin-binding growth factor that was originally discovered as the product of a retinoic acid-responsive gene. We previously demonstrated that MK-deficient mice exhibit a striking reduction of neointima formation in a restenosis model, which is reversed on systemic MK administration. In this study, we evaluated a strategy of using small interfering RNA (siRNA) targeting MK as a therapy for vein graft failure. We first made a highly effective siRNA to rabbit MK. Jugular vein-to-carotid artery interposition vein grafts, which are applied to a low flow condition, were made in Japanese white rabbits. Small interfering RNA mixed with atelocollagen was administrated to the external wall of grafted veins. Cy3-conjugated stabilized siRNA was used to confirm its stability and successful transfer into the vein graft wall. Neointimal hyperplasia was evaluated 4 weeks after the operation. The proliferation index and leukocyte infiltration were determined. MK expression was induced and reached the maximum level 7 days after operation. Fluorescence of Cy3-labeled siRNA could be detected in the graft wall even 7 days after operation. Knockdown of the gradually increasing expression was achieved by perivascular application of siRNA using atelocollagen. The intima-media ratio and the intima thickness at 28 days after grafting were both reduced >90% by this treatment compared with controls. This phenomenon was preceded by significant reductions of inflammatory cell recruitment to the vessel walls and subsequent cell proliferation in MK siRNA-treated grafts. These results suggest that midkine is a candidate molecular target for preventing vein graft failure. Furthermore, for clinical applications of siRNA, a single intraoperative atelocollagen-based nonviral delivery method could be a reliable approach to achieve maximal function of siRNA in vivo. This strategy may be a useful and practical form of gene therapy against human vein graft failure." @default.
• W2034118963 created "2016-06-24" @default.
• W2034118963 creator A5007801419 @default.
• W2034118963 creator A5042113860 @default.
• W2034118963 creator A5042205831 @default.
• W2034118963 creator A5053081524 @default.
• W2034118963 creator A5082519561 @default.
• W2034118963 date "2006-09-01" @default.
• W2034118963 modified "2023-10-13" @default.
• W2034118963 title "Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts" @default.
• W2034118963 cites W1516205253 @default.
• W2034118963 cites W1549511377 @default.
• W2034118963 cites W1611419331 @default.
• W2034118963 cites W1936557532 @default.
• W2034118963 cites W1963626132 @default.
• W2034118963 cites W1977288162 @default.
• W2034118963 cites W1985123699 @default.
• W2034118963 cites W1988871099 @default.
• W2034118963 cites W1988909864 @default.
• W2034118963 cites W1992346069 @default.
• W2034118963 cites W1994617747 @default.
• W2034118963 cites W1995003786 @default.
• W2034118963 cites W1995226504 @default.
• W2034118963 cites W1996126373 @default.
• W2034118963 cites W1999958985 @default.
• W2034118963 cites W2000225103 @default.
• W2034118963 cites W2000932006 @default.
• W2034118963 cites W2001189447 @default.
• W2034118963 cites W2002584827 @default.
• W2034118963 cites W2011339992 @default.
• W2034118963 cites W2020780927 @default.
• W2034118963 cites W2039179055 @default.
• W2034118963 cites W2040216156 @default.
• W2034118963 cites W2045778729 @default.
• W2034118963 cites W2050115452 @default.
• W2034118963 cites W2054131429 @default.
• W2034118963 cites W2066278450 @default.
• W2034118963 cites W2068743272 @default.
• W2034118963 cites W2070619582 @default.
• W2034118963 cites W2078698928 @default.
• W2034118963 cites W2079294175 @default.
• W2034118963 cites W2084556092 @default.
• W2034118963 cites W2087785808 @default.
• W2034118963 cites W2092663461 @default.
• W2034118963 cites W2093288623 @default.
• W2034118963 cites W2093468900 @default.
• W2034118963 cites W2104648430 @default.
• W2034118963 cites W2105523851 @default.
• W2034118963 cites W2109431998 @default.
• W2034118963 cites W2122553035 @default.
• W2034118963 cites W2129680188 @default.
• W2034118963 cites W2144961144 @default.
• W2034118963 cites W2150147414 @default.
• W2034118963 cites W2157939042 @default.
• W2034118963 cites W2161147419 @default.
• W2034118963 cites W2166413752 @default.
• W2034118963 cites W2172286707 @default.
• W2034118963 doi "https://doi.org/10.1016/j.jvs.2006.04.044" @default.
• W2034118963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16950446" @default.
• W2034118963 hasPublicationYear "2006" @default.
• W2034118963 type Work @default.
• W2034118963 sameAs 2034118963 @default.
• W2034118963 citedByCount "68" @default.
• W2034118963 countsByYear W20341189632012 @default.
• W2034118963 countsByYear W20341189632013 @default.
• W2034118963 countsByYear W20341189632014 @default.
• W2034118963 countsByYear W20341189632015 @default.
• W2034118963 countsByYear W20341189632016 @default.
• W2034118963 countsByYear W20341189632017 @default.
• W2034118963 countsByYear W20341189632018 @default.
• W2034118963 countsByYear W20341189632019 @default.
• W2034118963 countsByYear W20341189632020 @default.
• W2034118963 countsByYear W20341189632022 @default.
• W2034118963 countsByYear W20341189632023 @default.
• W2034118963 crossrefType "journal-article" @default.
• W2034118963 hasAuthorship W2034118963A5007801419 @default.
• W2034118963 hasAuthorship W2034118963A5042113860 @default.
• W2034118963 hasAuthorship W2034118963A5042205831 @default.
• W2034118963 hasAuthorship W2034118963A5053081524 @default.
• W2034118963 hasAuthorship W2034118963A5082519561 @default.
• W2034118963 hasBestOaLocation W20341189631 @default.
• W2034118963 hasConcept C126322002 @default.
• W2034118963 hasConcept C141071460 @default.
• W2034118963 hasConcept C142724271 @default.
• W2034118963 hasConcept C158074577 @default.
• W2034118963 hasConcept C170493617 @default.
• W2034118963 hasConcept C22615655 @default.
• W2034118963 hasConcept C2775960820 @default.
• W2034118963 hasConcept C2777339539 @default.
• W2034118963 hasConcept C2777562237 @default.
• W2034118963 hasConcept C2778095995 @default.
• W2034118963 hasConcept C2778283817 @default.
• W2034118963 hasConcept C2778583881 @default.
• W2034118963 hasConcept C2779751240 @default.
• W2034118963 hasConcept C2992686903 @default.
• W2034118963 hasConcept C502942594 @default.
• W2034118963 hasConcept C54009773 @default.
• W2034118963 hasConcept C54355233 @default.

• next